Novo Nordisk to launch the Ozempic pill in Q2 2026

Novo Nordisk (NVO) on Wednesday announced plans to launch some doses of its oral GLP-1 receptor agonist semaglutide under the ...

Novo Nordisk Warns of First Sales Drop Since Start of Ozempic

The once high-flying Danish drugmaker has struggled to fend off rivals in the weight-loss industry, especially Eli Lilly, ...

Hims & Hers launches Wegovy knockoff pill, Novo Nordisk vows to sue

Telehealth company Hims & Hers is launching a cheaper, off-brand version of the blockbuster weight loss pill Wegovy.

Novo Nordisk’s 2026 outlook in focus as competition pressures sales

For full-year 2025, sales are projected at DKK 307.62B, up from DKK 290.4B in 2024, with Wegovy contributing DKK 78.28B and Ozempic DKK 124.87B. EPS is forecast at DKK 23.28, compared with DKK 22.63 ...